Brought to you by 
SciClone gets rights to APR's RapidFilm ondansetron
08 Jul 2021
Executive Summary
SciClone Pharmaceuticals (cancer and infectious diseases) has licensed exclusive Chinese commercialization rights to APR Applied Pharma Research SA's (drug delivery and medical devices) RapidFilm formulation of the supportive oncology therapy ondansetron.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SciClone gets rights to APR's RapidFilm ondansetron
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice